Acer Therapeutics Inc.

1.22+0.0300+2.52%Vol 171.03K1Y Perf -59.52%
Jun 24th, 2022 16:00 DELAYED
BID1.20 ASK1.23
Open1.20 Previous Close1.19
Pre-Market- After-Market1.22
 - -  - -%
Target Price
11.00 
Analyst Rating
Strong Buy 1.00
Potential %
801.64 
Finscreener Ranking
 —    -
Insiders Trans % 3/6/12 mo.
-/-/100 
Value Ranking
★+     43.93
Insiders Value % 3/6/12 mo.
-/-/100 
Growth Ranking
 —    -
Insiders Shares Cnt. % 3/6/12 mo.
-/-/100 
Income Ranking
 —    -
Price Range Ratio 52W %
2.17 
Earnings Rating
Strong Sell
Market Cap18.68M 
Earnings Date
9th Aug 2022
Alpha0.01 Standard Deviation0.26
Beta1.27 

Today's Price Range

1.201.28

52W Range

1.163.77

5 Year PE Ratio Range

-4.00-1.90

Summary:

Sell

Technical Indicators: Neutral
Moving Averages: Strong Sell
Performance
1 Week
-30.68%
1 Month
-44.29%
3 Months
-57.49%
6 Months
-46.72%
1 Year
-59.52%
3 Years
-70.39%
5 Years
-80.02%
10 Years
-99.10%

TickerPriceChg.Chg.%
ACER1.220.03002.52
AAPL141.663.39002.45
GOOG2 370.76117.07005.19
MSFT267.708.84003.41
XOM86.901.69001.98
WFC40.762.86007.55
JNJ182.292.63001.46
FB196.640.99000.51
GE67.083.01004.70
JPM117.323.40002.98
Financial StrengthValueIndustryS&P 500US Markets
0.80
0.80
0.01
0.04
-4 429.70
Leverage Ratio -55.30
ProfitabilityValueIndustryS&P 500US Markets
-
-5 104.30
-5 083.00
-
-
RevenueValueIndustryS&P 500US Markets
360.00K
0.02
-
-
Earnings HistoryEstimateReportedSurprise %
Q01 2022-0.18-0.49-172.22
Q04 2021-0.08-0.31-287.50
Q03 2021-0.28-0.2317.86
Q02 2021-0.36-0.2336.11
Q01 2021-0.41-0.1173.17
Q04 2020-0.43-0.50-16.28
Q03 2020-0.44-0.51-15.91
Q02 2020-0.38-0.56-47.37
Earnings Per EndEstimateRevision %Trend
6/2022 QR-0.34-21.43Negative
9/2022 QR-0.71-10.94Negative
12/2022 FY-2.29-11.71Negative
12/2023 FY-1.06-6.00Negative
Next Report Date9th Aug 2022
Estimated EPS Next Report-0.57
Estimates Count2
EPS Growth Next 5 Years %-
Volume Overview
Volume171.03K
Shares Outstanding15.31K
Shares Float10.43M
Trades Count283
Dollar Volume210.80K
Avg. Volume323.47K
Avg. Weekly Volume290.09K
Avg. Monthly Volume181.57K
Avg. Quarterly Volume498.76K

Acer Therapeutics Inc. (NASDAQ: ACER) stock closed at 1.22 per share at the end of the most recent trading day (a 2.52% change compared to the prior day closing price) with a volume of 171.03K shares and market capitalization of 18.68M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 18 people. Acer Therapeutics Inc. CEO is Chris Schelling.

The one-year performance of Acer Therapeutics Inc. stock is -59.52%, while year-to-date (YTD) performance is -46.49%. ACER stock has a five-year performance of -80.02%. Its 52-week range is between 1.1634 and 3.77, which gives ACER stock a 52-week price range ratio of 2.17%

Acer Therapeutics Inc. currently has a PE ratio of -1.30, a price-to-book (PB) ratio of 16.46, a price-to-sale (PS) ratio of 74.85, a price to cashflow ratio of 31.40, a PEG ratio of 2.32, a ROA of -54.26%, a ROC of -147.90% and a ROE of 14 672.60%. The company’s profit margin is -%, its EBITDA margin is -5 083.00%, and its revenue ttm is $360.00 Thousand , which makes it $0.02 revenue per share.

Of the last four earnings reports from Acer Therapeutics Inc., there were 2 positive earnings surprise and 2 negative earnings surprise. The company has EPS estimate of $-0.57 for the next earnings report. Acer Therapeutics Inc.’s next earnings report date is 09th Aug 2022.

The consensus rating of Wall Street analysts for Acer Therapeutics Inc. is Strong Buy (1), with a target price of $11, which is +801.64% compared to the current price. The earnings rating for Acer Therapeutics Inc. stock is Strong Sell (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Acer Therapeutics Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Acer Therapeutics Inc. has a Sell technical analysis rating based on Technical Indicators (ADX : 15.95, ATR14 : 0.17, CCI20 : -141.52, Chaikin Money Flow : -0.31, MACD : -0.24, Money Flow Index : 6.48, ROC : -44.29, RSI : 24.44, STOCH (14,3) : 4.05, STOCH RSI : 0.12, UO : 18.61, Williams %R : -95.95), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Acer Therapeutics Inc. in the last 12-months were: Stephen Aselage (Buy at a value of $20 622)

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
2 (100.00 %)
2 (100.00 %)
2 (100.00 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Hold
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingStrong Buy
1.00
Strong Buy
1.00
Strong Buy
1.00

Acer Therapeutics Inc.

Acer Therapeutics Inc operates as a pharmaceutical company. Principally, it is focused on the acquisition, development, and commercialization of therapies for patients with serious rare and ultra-rare diseases with a critical unmet medical need. The company's clinical pipeline includes three categories of severe genetic disorders namely EDSIVO for vEDS, and ACER-001 for urea cycle disorders and maple syrup urine disease.

CEO: Chris Schelling

Telephone: +1 844 902-6100

Address: 300 Washington Street, Newton 02458, MA, US

Number of employees: 18

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

63%38%

Bearish Bullish

68%32%

Bearish Bullish

61%39%

TipRanks News for ACER

Wed, 22 Jun 2022 10:15 GMT Analysts Top Healthcare Picks: Acer Therapeutics (ACER), EyePoint Pharmaceuticals (EYPT)

- TipRanks. All rights reserved.

Mon, 04 Apr 2022 15:20 GMT Analysts Are Bullish on These Healthcare Stocks: Acer Therapeutics (ACER), Curis (CRIS)

- TipRanks. All rights reserved.

Tue, 11 Jan 2022 11:15 GMT Analysts Top Healthcare Picks: Acer Therapeutics (ACER), Cerevel Therapeutics Holdings (CERE)

- TipRanks. All rights reserved.

News

Stocktwits